Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. reports clinical and corporate developments as a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody combining an EGFR-directed monoclonal antibody with a domain that binds human TGF-beta, with company updates focused on first-line recurrent or metastatic HPV-negative HNSCC and the FORTIFI-HN01 pivotal trial.
Recurring news also includes quarterly financial results, business updates, public equity financing, common stock and pre-funded warrant offerings, Nasdaq inducement grants, and executive appointments tied to clinical development, medical affairs and commercial readiness.
Bicara Therapeutics (NASDAQ: BCAX) reported preliminary Phase 1b expansion cohort data evaluating 750 mg weekly ficerafusp alfa plus pembrolizumab in first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (1L HPV-negative R/M HNSCC).
Key readouts (July 9, 2025 cutoff) in the efficacy-evaluable population (n=30): 57% objective response rate (17/30; 15 PR, 2 CR) and 83% disease control rate (25/30). Complete, prolonged neutralization of TGF-β1 was observed and safety was consistent with the known profile. Data inform dose selection for the pivotal FORTIFI-HN01 trial and supported the company’s FDA Breakthrough Therapy Designation. Results will be presented at ESMO Asia 2025 with a company webcast and conference call on Dec 6, 2025 at 9:00 a.m. ET.
Bicara Therapeutics (NASDAQ: BCAX) reported Q3 2025 results and a business update on Nov 10, 2025. The FDA granted Breakthrough Therapy Designation for ficerafusp alfa plus pembrolizumab in 1L HPV-negative R/M HNSCC. The company continues to enroll the pivotal Phase 2/3 FORTIFI-HN01 trial and plans multiple Phase 1b data presentations, including a 750mg cohort at ESMO Asia 2025. Financials: $407.6M cash, cash equivalents and investments as of Sept 30, 2025; cash expected to fund operations into H1 2029. Q3 operating spend included R&D $33.0M and G&A $7.7M; net loss $36.3M.
Bicara Therapeutics (Nasdaq: BCAX) announced the U.S. FDA granted Breakthrough Therapy Designation to ficerafusp alfa plus pembrolizumab for first-line treatment of metastatic or unresectable, recurrent HPV-negative HNSCC with PD-L1 CPS ≥1 (excluding HPV-positive oropharyngeal SCC) on Oct 13, 2025.
BTD was supported by Phase 1/1b cohorts presented at ASCO 2025 showing a median duration of response 21.7 months and median overall survival 21.3 months with a favorable safety profile. The designation enables increased FDA interaction, senior leadership involvement, and eligibility for rolling and priority review and supports the ongoing pivotal FORTIFI-HN01 trial.
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in three major upcoming healthcare investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3, 10:55 a.m. ET), the Wells Fargo Healthcare Conference (September 3, 2:15 p.m. ET), and the Morgan Stanley Global Healthcare Conference (September 8, 4:05 p.m. ET). All fireside chat presentations will be available via webcast through Bicara's Investor Relations website.
Bicara Therapeutics (NASDAQ:BCAX) reported Q2 2025 financial results and provided updates on its lead drug candidate ficerafusp alfa. The company highlighted strong Phase 1/1b trial results presented at ASCO 2025, showing a 54% confirmed objective response rate in HPV-negative head and neck cancer patients, with median duration of response of 21.7 months.
The company maintains a robust financial position with $436.6 million in cash, expected to fund operations into H1 2029. Q2 2025 saw increased R&D expenses of $24.8 million and a net loss of $27.4 million. The ongoing pivotal Phase 2/3 FORTIFI-HN01 trial continues enrollment, with additional Phase 1/1b expansion cohort data expected by Q1 2026.
Rice Biotech Launch Pad has appointed Carolyn Ng, a business unit partner at TPG Life Sciences Innovations, to its external advisory board. Ng brings significant expertise in biotech and company building, with extensive experience guiding early to midstage companies across various therapeutic areas.
Currently leading investments at TPG Life Sciences Innovations in San Francisco, Ng serves on multiple boards including Mbrace Therapeutics, Adcendo Aps, and Bicara Therapeutics (NASDAQ: BCAX). Her appointment marks her as the 16th member of the Launch Pad's external advisory board, joining leaders from various prestigious institutions and companies.
The Rice Biotech Launch Pad, based in Houston, focuses on accelerating the translation of Rice University's health and medical technology discoveries into practical medical solutions.
- 64% objective response rate, with 21% achieving complete response
- Median progression-free survival of 9.8 months
- 12-month overall survival rate of 61%
- Median overall survival exceeding 20 months (not yet reached)
Bicara Therapeutics (NASDAQ: BCAX) reported its Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug candidate, ficerafusp alfa, a first-in-class dual-action bifunctional EGFR/TGF-β antibody, continues to advance in clinical trials. The company is currently conducting FORTIFI-HN01, a pivotal Phase 2/3 trial for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
Updated data from the ongoing Phase 1/1b trial will be presented at the 2025 ASCO Annual Meeting. The company reported $462.1 million in cash and cash equivalents as of March 31, 2025, expected to fund operations into first half of 2029. Q1 2025 saw a net loss of $36.8 million, with R&D expenses of $34.3 million and G&A expenses of $7.5 million.